Trials / Unknown
UnknownNCT04923100
Therapeutic Effect of New Biologics in Crohn's Disease
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 17 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
New types of biologics have brought advantages in therapy strategies for Crohn's disease. However, clinical data evaluating their efficacy and adverse in China is lacking. We aimed to evaluate the short-term and long-term therapeutic effect as well as drug adverse of Ustekinumab (UST) and Vedolizumab (VED). Besides, we aim to figure out the independent factors predicting the effectiveness of new biologics. Relations between drug exposure (trough concentration and antibody concentration) and therapeutic efficacy are study in-depth by this retrospective observational study.
Conditions
Timeline
- Start date
- 2021-06-10
- Primary completion
- 2024-03-29
- Completion
- 2025-03-29
- First posted
- 2021-06-11
- Last updated
- 2023-12-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04923100. Inclusion in this directory is not an endorsement.